Navigation Links
New Drug Slows Advanced Kidney Cancer
Date:1/26/2010

Pazopanib may double time to disease progression, study finds

TUESDAY, Jan. 26 (HealthDay News) -- Treating advanced kidney cancer patients with the drug pazopanib (Votrient) slowed their disease progression by 54 percent, a new study has found.

The phase 3 study included 233 patients with previously untreated kidney cancer (also known as renal cell carcinoma) that was locally advanced or had spread, and 202 patients with renal cell carcinoma who had previously been treated with cytokine therapy (interferon or interleukin). The patients were randomly assigned to take pazopanib tablets (290 patients) or a placebo drug (145 patients).

In the pazopanib group, it took an average 9.2 months for the cancer to progress, vs. an average 4.2 months in the placebo group. The difference was greatest in previously untreated patients (11.1 months for the pazopanib group and 2.8 months for the placebo group), but also was found among patients previously treated with cytokines (7.4 months in the pazopanib group vs. 4.2 months in placebo group).

Common side effects of pazopanib treatment included diarrhea (52 percent), high blood pressure (40 percent), hair color changes (38 percent), nausea (26 percent), weight loss (22 percent) and vomiting (21 percent).

The data from this study, published online Jan. 25 in the Journal of Clinical Oncology, was used by the U.S. Food and Drug Administration to approve pazopanib in October 2009 for the treatment of advanced renal cell carcinoma.

Pazopanib inhibits the development of blood vessels that tumors need to grow and spread.

"Advanced renal cell carcinoma remains a challenging disease, but treatment has improved with the introduction of new targeted therapies over the past year -- including pazopanib, which targets multiple pathways within cancer cells," study author Dr. Cora Sternberg, chief of the medical oncology department at the San Camillo and Forlanini Hospital in Rome, Italy, said in a news release from the American Society of Clinical Oncology.

More information

The American Cancer Society has more about kidney cancer.



-- Robert Preidt



SOURCE: American Society of Clinical Oncology, news release, Jan. 25, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Genetic Variant Slows AIDS Progression
2. Wistar researchers show targeting normal cells in tumors slows growth
3. Drinking coffee slows progression of liver disease in chronic hepatitis C sufferers
4. Prime Therapeutics 2009 Drug Trend Insights Shows Drug Spending Slows to Lowest Rate on Record
5. Vaccine slows progression of skeletal muscle disorder
6. Male Cosmetic Surgery Slows Down While Female Cosmetic Surgery Advances
7. AIDS Drug Slows Spread of Deadly Childhood Brain Cancer
8. Chondroitin slows progression and relieves symptoms of knee osteoarthritis
9. Old gastrointestinal drug slows aging, McGill researchers say
10. Adult-onset diabetes slows mental functioning in several ways, with deficits appearing early
11. Vitamin K Slows Insulin Resistance in Older Men
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... ... offices in Pasco and Richland, is initiating a charity drive to support the ... from a recent automobile collision. , On October 29th of this year, ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Justin Veatch Fund ... (NCADD) is recommending the film Whispering Spirits and its discussion guide for ... as an education tool in the war against teen drug abuse. NCADD is ...
(Date:12/9/2016)... ... December 09, 2016 , ... The ... Hotel in New York, NY, on December 3rd, to benefit Holy Name Medical ... the annual event, which raised over $1 million - the largest event in ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Quality Insights beginning January 1, 2017. The name change aligns the entire ... measuring and improving health care quality. , “We are very proud of the ...
(Date:12/8/2016)... ... December 08, 2016 , ... ZyDoc , ... Processing–Enabled and Conventional Data Capture Methods for Input to Electronic Health Records: A ... Results of the comparative usability study demonstrate that a dictation-based method (“NLP Entry”) ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... Patient ... loss of blood during surgeries, lowering the risks of neurological ... risks of SSIs. The patient warming systems can be segmented ... systems.These benefits in turn reduce the stay at hospitals thus, ...
(Date:12/8/2016)... 8, 2016 Global Interventional Radiology Market: ... global interventional radiology market analyzes the current and ... an elaborate executive summary, including a market snapshot ... sub-segments. The research is a combination of ... bulk of our research efforts along with information ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... largest share of the market in 2016 and is ... can be attributed to a large number of surgical ... hold the largest share in the patient temperature management ... such as reducing loss of blood during surgeries, lowering ...
Breaking Medicine Technology: